| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.5 - Atopic Dermatitis, Diagnosed | 2013 | Germany | IgE | 140 | 0.000 | 20130111, Ott H
| | 1.11 - Esophagitis, Diagnosed | 2013 | Switzerland | IgE | 35 | 2.860 | 20130605, Simon D
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2013 | Brazil | IgE | 11 | 63.630 | 20130429, Bueno de Sa A
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 0.000 | 20120528, Patelis A
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 2.020 | 20110223, De Knop KJ
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2012 | France | IgE | 97 | 55.000 | 20120706, Garnier L
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 0.000 | 20120528, Patelis A
| | 6.5 - Occupational Exposure | 2012 | South Africa | IgE | 85 | 3.530 | 20120404, Singh T
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 3.700 | 20110223, De Knop KJ
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 0.690 | 20100301, Scala E
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Italy / Austria / Switzerland / Netherlands | IgE | 101 | 16.830 | 20101118, Bublin M
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | Germany | IgE | 52 | 50.000 | 20100423, Ott H
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Italy / Austria / Switzerland / Netherlands | IgE | 48 | 10.420 | 20101118, Bublin M
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 2.702 | 20090826, Ebo DG
| | 1.1 - Asymptomatic | 2009 | Belgium | BPT | 26 | 0.000 | 20091121, Ebo DG
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 77.270 | 20091121, Ebo DG
| | 3.2.1 - Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 0.000 | 20091121, Ebo DG
| | 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 0.000 | 20091005, Ott H
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2009 | Japan | IgE | 14 | 42.800 | 20090520, Yagami A
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2009 | Japan | SPT | 14 | 21.400 | 20090520, Yagami A
| | 3.2.1 - Source Sensitized (IgE) | 2009 | Italy | IgE | 7 | 0.000 | 20091030, Quercia O
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | Portugal | IgE | 5 | 40.000 | 20080904, Rodrigues Alves R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2007 | Finland | IgE | 79 | 28.000 | 20070910, Palasuo T
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2007 | Spain | IgE | 74 | 49.000 | 20070910, Palasuo T
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2007 | United States | IgE | 62 | 71.000 | 20070910, Palasuo T
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2006 | Spain | IgE | 23 | 43.500 | 20060324, Sanz ML
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2005 | Spain | IgE | 31 | 54.800 | 20051208, Pamies R
| | 3.1.2 - Source Sensitized - High Exposure (SPT) | 2003 | United States | SPT | 62 | 65.000 | 2003, Bernstein DI
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2000 | Canada | SPT | 29 | 62.100 | 2000, Yip L
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2000 | United States | IgE | 28 | 36.000 | 2000, Yeang HY
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2000 | Finland | IgE | 8 | 13.000 | 2000, Yeang HY
| | 3.2.2 - Source Sensitized - High Exposure (IgE) | 1996 | United States | IgE | 57 | 56.000 | 1996, Slater JE
| | 3.2.2 - Source Sensitized - High Exposure (IgE) | 1996 | United States | IgE | 13 | 92.000 | 1996, Slater JE
|
|
Loading...
Hev b 5
